Harpoon Therapeutics, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa)
Clinical trials sponsored by Harpoon Therapeutics, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa), explained in plain language.
-
New hope for Tough-to-Treat myeloma: early trial of HPN217 underway
Disease control OngoingThis early-stage study is testing a new drug called HPN217 in about 100 people whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. While not a cure,…
Phase: PHASE1 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 26, 2026 12:44 UTC
-
New hope for hard-to-treat cancers: experimental drug targets DLL3
Disease control OngoingThis study tests an experimental drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have DLL3 protein. The goal is to find the safest dose and see if it helps shrink tumors. About 232 adults will take p…
Phase: PHASE1, PHASE2 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 26, 2026 12:03 UTC